Please assess the completion status of the following clinical trial:

Trial Title: Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening~* Male and female children aged 4-11 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 60-90%~* Ability to perform spirometry~* Demonstrate 12% airways reversibility~Exclusion Criteria:~* Require continuous treatment with beta-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids~* Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic diseases

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Albuterol-HFA-BAI (Type: EXPERIMENTAL): ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
- Placebo-HFA-BAI (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).